Arcellx (ACLX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
107.9M
Operating Income
-137.6M
-127.46%
Net Income
-107.3M
-99.46%
Balance Sheet Metrics
Total Assets
711.3M
Total Liabilities
256.5M
Shareholders Equity
454.8M
Debt to Equity
0.56
Cash Flow Metrics
Operating Cash Flow
-118.4M
Free Cash Flow
-96.9M
Revenue & Profitability Trend
Arcellx Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 107.9M | 110.3M | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 245.5M | 200.2M | 191.3M | 65.0M | 32.1M |
| Operating Income | -137.6M | -89.9M | -191.3M | -65.0M | -32.1M |
| Pre-tax Income | -105.3M | -70.0M | -188.7M | -65.0M | -32.1M |
| Income Tax | 2.1M | 663.0K | 0 | - | - |
| Net Income | -107.3M | -70.7M | -188.7M | -65.0M | -32.1M |
| EPS (Diluted) | - | -$1.47 | -$5.19 | -$1.94 | -$1.47 |
Income Statement Trend
Arcellx Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 599.3M | 716.4M | 266.9M | 112.8M | 49.4M |
| Non-Current Assets | 112.0M | 108.8M | 47.0M | 16.0M | 8.3M |
| Total Assets | 711.3M | 825.1M | 313.8M | 128.8M | 57.7M |
| Liabilities | |||||
| Current Liabilities | 125.4M | 118.2M | 56.7M | 14.8M | 5.3M |
| Non-Current Liabilities | 131.1M | 221.5M | 52.2M | 235.5M | 116.1M |
| Total Liabilities | 256.5M | 339.8M | 108.9M | 250.3M | 121.4M |
| Equity | |||||
| Total Shareholders Equity | 454.8M | 485.4M | 205.0M | -121.5M | -63.7M |
Balance Sheet Composition
Arcellx Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -107.3M | -70.7M | -188.7M | -65.0M | -32.1M |
| Operating Cash Flow | -118.4M | 221.2M | -91.1M | -56.2M | -31.8M |
| Investing Activities | |||||
| Capital Expenditures | -13.4M | -21.4M | -2.3M | -5.8M | -888.0K |
| Investing Cash Flow | -183.0M | -154.5M | -117.7M | -80.0M | -888.0K |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -39.8M | 270.3M | 250.2M | 118.0M | 41.6M |
| Free Cash Flow | -96.9M | 186.1M | -101.6M | -60.0M | -29.6M |
Cash Flow Trend
Arcellx Key Financial Ratios
Valuation Ratios
Forward P/E
-28.28
Price to Book
8.40
Price to Sales
45.64
PEG Ratio
-28.28
Profitability Ratios
Profit Margin
-211.46%
Operating Margin
-847.56%
Return on Equity
-35.56%
Return on Assets
-16.69%
Financial Health
Current Ratio
4.93
Debt to Equity
12.76
Beta
0.28
Per Share Data
EPS (TTM)
-$2.99
Book Value per Share
$7.57
Revenue per Share
$1.42
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| aclx | 3.5B | - | 8.40 | -35.56% | -211.46% | 12.76 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.